Department of Biomedical Sciences, University of Sassari, 07100, Sassari, Italy.
Department of Cardiology, The Second Affiliated Hospital of Shantou University Medical College, 515041, Shantou, China.
Cardiovasc Diabetol. 2024 Sep 28;23(1):346. doi: 10.1186/s12933-024-02434-5.
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed nonalcoholic fatty liver disease (NAFLD), poses a significant global health challenge due to its increasing prevalence and strong association with cardiovascular disease (CVD). This comprehensive review summarizes the current knowledge on the MASLD-CVD relationship, compares analysis of how different terminologies for fatty liver disease affect cardiovascular (CV) risk assessment using different diagnostic criteria, explores the pathophysiological mechanisms connecting MASLD to CVD, the influence of MASLD on traditional CV risk factors, the role of noninvasive imaging techniques and biomarkers in the assessment of CV risk in patients with MASLD, and the implications for clinical management and prevention strategies. By incorporating current research and clinical guidelines, this review provides a comprehensive overview of the complex interplay between MASLD and cardiovascular health.
代谢相关脂肪性肝病（MASLD），以前称为非酒精性脂肪性肝病（NAFLD），由于其患病率不断增加，并且与心血管疾病（CVD）密切相关，因此成为一个重大的全球健康挑战。这篇综合综述总结了 MASLD 与 CVD 关系的最新知识，比较了使用不同诊断标准时不同脂肪性肝病术语对心血管（CV）风险评估的分析，探讨了将 MASLD 与 CVD 联系起来的病理生理机制，MASLD 对传统 CV 危险因素的影响，非侵入性成像技术和生物标志物在 MASLD 患者 CV 风险评估中的作用，以及对临床管理和预防策略的影响。通过结合当前的研究和临床指南，本综述全面概述了 MASLD 和心血管健康之间复杂的相互作用。
